This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kelly, T. Articles by Sanderson, R. D. Search for Related Content PubMed PubMed Citation Articles by Kelly, T. Articles by Sanderson, R. D.

High Heparanase Activity in Multiple Myeloma Is Associated with Elevated Microvessel Density

¹ Departments of Pathology,
⁴ Anatomy and Neurobiology,
³ Myeloma Institute for Research and Therapy, Arkansas Cancer Research Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas, and
² ImClone Systems Incorporated, New York, New York

Heparanase is an enzyme that cleaves heparan sulfate chains of proteoglycans, and its expression has been associated with increased growth, metastasis, and angiogenesis of some tumors. Because myeloma tumor cells express high levels of the syndecan-1 heparan sulfate proteoglycan and because these tumors grow as highly vascularized aggregates within the bone marrow, we analyzed the activity, expression, and function of heparanase in myeloma patients. Analysis of heparanase activity in the plasma isolated from bone marrow biopsies of 100 patients reveals 86 positive for heparanase activity and 14 negative. The bone marrow samples can be further divided into three categories of heparanase activity, high activity (42 patients), low activity (44 patients), and negative (14 patients). In contrast to the bone marrow plasma, levels of heparanase activity in peripheral blood plasma of 29 myeloma patients were either negative or low, suggesting that in multiple myeloma, heparanase functions in the local microenvironment of the bone marrow and its activity is not significantly elevated systemically. Immunohistochemistry reveals that patients with high levels of heparanase activity often have tumor cells with intense staining for the enzyme. Interestingly, a marked heterogeneity among tumor cells was noted, with clusters of heavily stained cells surrounded by cells with weak or negative staining for heparanase. Analysis of microvessel density reveals a strikingly higher concentration of vessels in patients with high heparanase activity (78.96 vessels/mm²) as compared with patients negative for heparanase activity (25.03 vessels/mm²). When human myeloma cells transfected with the cDNA for heparanase are implanted in severe combined immunodeficient (SCID) mice, the resulting tumors exhibited a significantly higher microvessel density than did tumors established with control cells. Thus, expression of heparanase appears to play a direct role in enhancing microvessel density in these myeloma tumors. Because heparanase is known to stimulate angiogenesis, and because high microvessel density is associated with poor prognosis in myeloma, we conclude that heparanase expression likely plays an important role in regulating the growth and progression of myeloma, and that therapies designed to block heparanase activity may aid in controlling this cancer.

This article has been cited by other articles:

				C. Chomel, A. Cazes, C. Faye, M. Bignon, E. Gomez, C. Ardidie-Robouant, A. Barret, S. Ricard-Blum, L. Muller, S. Germain, et al. Interaction of the coiled-coil domain with glycosaminoglycans protects angiopoietin-like 4 from proteolysis and regulates its antiangiogenic activity FASEB J, March 1, 2009; 23(3): 940 - 949. [Abstract] [Full Text] [PDF]

				V. Cohen-Kaplan, I. Doweck, I. Naroditsky, I. Vlodavsky, and N. Ilan Heparanase Augments Epidermal Growth Factor Receptor Phosphorylation: Correlation with Head and Neck Tumor Progression Cancer Res., December 15, 2008; 68(24): 10077 - 10085. [Abstract] [Full Text] [PDF]

				A. Purushothaman, L. Chen, Y. Yang, and R. D. Sanderson Heparanase Stimulation of Protease Expression Implicates It as a Master Regulator of the Aggressive Tumor Phenotype in Myeloma J. Biol. Chem., November 21, 2008; 283(47): 32628 - 32636. [Abstract] [Full Text] [PDF]

				B. Burington, B. Barlogie, F. Zhan, J. Crowley, and J. D. Shaughnessy Jr. Tumor Cell Gene Expression Changes Following Short-term In vivo Exposure to Single Agent Chemotherapeutics are Related to Survival in Multiple Myeloma Clin. Cancer Res., August 1, 2008; 14(15): 4821 - 4829. [Abstract] [Full Text] [PDF]

				Y. Yang, V. MacLeod, Y. Dai, Y. Khotskaya-Sample, Z. Shriver, G. Venkataraman, R. Sasisekharan, A. Naggi, G. Torri, B. Casu, et al. The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy Blood, September 15, 2007; 110(6): 2041 - 2048. [Abstract] [Full Text] [PDF]

				I. Cohen, B. Maly, I. Simon, A. Meirovitz, E. Pikarsky, E. Zcharia, T. Peretz, I. Vlodavsky, and M. Elkin Tamoxifen Induces Heparanase Expression in Estrogen Receptor Positive Breast Cancer Clin. Cancer Res., July 15, 2007; 13(14): 4069 - 4077. [Abstract] [Full Text] [PDF]

				K. Mahtouk, D. Hose, P. Raynaud, M. Hundemer, M. Jourdan, E. Jourdan, V. Pantesco, M. Baudard, J. De Vos, M. Larroque, et al. Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma Blood, June 1, 2007; 109(11): 4914 - 4923. [Abstract] [Full Text] [PDF]

				Y. Yang, V. MacLeod, H.-Q. Miao, A. Theus, F. Zhan, J. D. Shaughnessy Jr., J. Sawyer, J.-P. Li, E. Zcharia, I. Vlodavsky, et al. Heparanase Enhances Syndecan-1 Shedding: A NOVEL MECHANISM FOR STIMULATION OF TUMOR GROWTH AND METASTASIS J. Biol. Chem., May 4, 2007; 282(18): 13326 - 13333. [Abstract] [Full Text] [PDF]

				A. Zetser, Y. Bashenko, E. Edovitsky, F. Levy-Adam, I. Vlodavsky, and N. Ilan Heparanase Induces Vascular Endothelial Growth Factor Expression: Correlation with p38 Phosphorylation Levels and Src Activation Cancer Res., February 1, 2006; 66(3): 1455 - 1463. [Abstract] [Full Text] [PDF]

				T. Okawa, Y. Naomoto, T. Nobuhisa, M. Takaoka, T. Motoki, Y. Shirakawa, T. Yamatsuji, H. Inoue, M. Ouchida, M. Gunduz, et al. Heparanase Is Involved in Angiogenesis in Esophageal Cancer through Induction of Cyclooxygenase-2 Clin. Cancer Res., November 15, 2005; 11(22): 7995 - 8005. [Abstract] [Full Text] [PDF]

				T. Kelly, L. J. Suva, Y. Huang, V. MacLeod, H.-Q. Miao, R. C. Walker, and R. D. Sanderson Expression of Heparanase by Primary Breast Tumors Promotes Bone Resorption in the Absence of Detectable Bone Metastases Cancer Res., July 1, 2005; 65(13): 5778 - 5784. [Abstract] [Full Text] [PDF]

				P. Beckhove, B. M. Helmke, Y. Ziouta, M. Bucur, W. Dorner, C. Mogler, G. Dyckhoff, and C. Herold-Mende Heparanase Expression at the Invasion Front of Human Head and Neck Cancers and Correlation with Poor Prognosis Clin. Cancer Res., April 15, 2005; 11(8): 2899 - 2906. [Abstract] [Full Text] [PDF]

				T. Ogishima, H. Shiina, J. E. Breault, L. Tabatabai, W. W. Bassett, H. Enokida, L.-C. Li, T. Kawakami, S. Urakami, L. A. Ribeiro-Filho, et al. Increased Heparanase Expression Is Caused by Promoter Hypomethylation and Up-Regulation of Transcriptional Factor Early Growth Response-1 in Human Prostate Cancer Clin. Cancer Res., February 1, 2005; 11(3): 1028 - 1036. [Abstract] [Full Text] [PDF]

				Y. Yang, V. MacLeod, M. Bendre, Y. Huang, A. M. Theus, H.-Q. Miao, P. Kussie, S. Yaccoby, J. Epstein, L. J. Suva, et al. Heparanase promotes the spontaneous metastasis of myeloma cells to bone Blood, February 1, 2005; 105(3): 1303 - 1309. [Abstract] [Full Text] [PDF]

				E. Edovitsky, M. Elkin, E. Zcharia, T. Peretz, and I. Vlodavsky Heparanase Gene Silencing, Tumor Invasiveness, Angiogenesis, and Metastasis J Natl Cancer Inst, August 18, 2004; 96(16): 1219 - 1230. [Abstract] [Full Text] [PDF]

				S. Gingis-Velitski, A. Zetser, M. Y. Flugelman, I. Vlodavsky, and N. Ilan Heparanase Induces Endothelial Cell Migration via Protein Kinase B/Akt Activation J. Biol. Chem., May 28, 2004; 279(22): 23536 - 23541. [Abstract] [Full Text] [PDF]